Purpose: The purpose of this study was to determine, within the first-year posthead and neck cancer (HNC) diagnosis, the contribution of past and upon HNC psychiatric diagnoses (ie, substance use disorder, major depressive disorder, and anxiety disorder) to the extent (ie, cumulated dose) of opioid prescription.
The literature on opioid continuation in general oncology has found associations with age, sex, psychiatric conditions, alcohol dependency, symptom severity, and smoking status. 12, 13 A single retrospective medical chart-review study conducted in HNC has shown a substantial level of opioid prescriptions post-HNC treatment (63% at 3 months and 33% at 6 months; n = 70), with post-treatment opioid continuation associated with a charted history of alcohol dependency and a higher radiation dose. 14 Our aim was to further pursue this line of research using a stronger prospective longitudinal design including structured clinical interviews.
The purpose of this study was to determine, 1 year post-HNC diagnosis, (1) the cumulative standardized morphine milligram equivalent (MME) dose of prescribed opioids pre-, during, and post-HNC treatment; (2) the contribution of past-and upon-HNC diagnosis (ie, cumulated MME) of opioid prescription over 1 year; and (3) the clinical correlates of MME dose. Our a-priori conceptual model of predictors and confounds can be found in Figure 1 . Our main hypothesis was that HNC patients presenting a lifetime and/or upon HNC diagnosis of MDD, AD, or SUD would be predisposed to receive significantly higher MME doses than those without. We also explored medical and clinical correlates of High vs Low MME/day subgroups as defined by CDC guidelines. 15, 16 2 | METHODS
| Design
Patients completed the Structured Clinical Interview for DSM-IV diagnoses (SCID-I) of MDD, AD, and SUD and a battery of selfadministered measures upon HNC diagnosis (ie, pre-treatment).
Opioid prescriptions as well as sociodemographic, medical, and confound variables were collected through medical chart reviews, corroborated by a centralized prescription registry.
| Eligibility and exclusion criteria
Patients included in the study were (1) newly diagnosed with a first occurrence of primary HNC <2 weeks at referral; (2) ≥18 years; (3) alert and capable of giving free and informed consent; and (4) able
Predictors of cumulative dose of opioid prescriptions among patients with HNC Note: The hypothesized direction of the relationship is in parentheses.
to read English or French. Patients were excluded if they had (1) a Karnofsky Performance Scale score < 60; and (2) an expected survival <6 months per the treating team. 
| Recruitment

| Data collection
Following consent, patients completed baseline self-administered measures and an individual SCID-I interview. Self-administered measures were repeated at 3, 6, and 12 months. Measures were selected based on psychometric properties, ability to be self-administered, and use in oncology.
| Primary outcome measure
The primary outcome was a 12-month time course characterization of opioid prescriptions from time of diagnosis, including name of opioid, dose, method and mode of administration, date, and prescribing physician and service. Doses were cumulated for each patient and translated into MME units using CDC guidelines. 15 Data on neuropathic pain and lymphedema were tracked through medical charts, as well as sociodemographic, medical, and confounding variables. The sample was divided into Low MME vs High MME groups based on CDC guidelines considering a dose of 20MME/day as rendering a risk for opioid toxicity (dose established in chronic, non-cancer population). 
| Chart reviews
Basic sociodemographics and the following medical variables were collected at baseline and 3, 6, and 12 months: cancer stage and type (SCC, HPV-16), treatment (surgery, radiotherapy, and/or chemotherapy), disease progression/recurrence, and death. Chart reviews were supplemented by follow-up questionnaires to cover psychosocial oncology service use, including psychiatric medication prescriptions at baseline and 3, 6, and 12 months follow-up. A centralized prescription registry was consulted to complement chart reviews.
| Statistical analyses
Data were entered in SPSS 22.0 and analyses conducted on a Box-Cox transformation of the primary outcome, considering the non-normal distribution. Simple analyses used independent sample t-tests and
Pearson correlations, and predictors were combined in a one level multiple linear regression. Low vs High MME subgroups were characterized with independent sample t-tests and Chi Square. The cumulated 12-month MME average in patients prescribed opioids was 4042.0MME (s.d. = 15 319.3; range = 0.7-168 101.1; 11.1MME/ day; see Figure 2 ) with a post-treatment average of 1603.8MME
(s.d. = 7312.1; range = 0.0-76 114; 4.4MME/day). Opioids prescribed included codeine, fentanyl, hydromorphone, methadone, morphine, and oxycodone. Methadone was used for opioid dependency in one patient for a total dose of 652MME and was excluded from the primary outcome. 17 The High MME subgroup (≥20MME/day 18, 19 ) comprised 15 patients (n = 15/189; 7.9%), whereas the Low MME comprised 173
(n = 173/189; 91.5%). The cumulated 12-month MME average for the High MME group was 31 712.0MME (s.d. = 39 159.7; median = 12 534.3; range = 7401.0-167 981.1; 86.9MME/day) with a post-treatment average of 13 040.8MME (s.d. = 20 001.7; median = 3688.0; range = 0-76 114.0; 35.7MME/day). In the Low group, the cumulated 12-month average was 734.4MME (s.
d. = 1286.9; median = 226.9; range = 0-7066.5; 2.01MME/day) with a post-treatment average of 252.9MME (s.d. = 703.5; median = 0; range = 0-4737.0; 0.69MME/day).
See Table 1 with a trend towards under-prescription in AD (see Table 2 ). There was no relationship between staging (early/advanced) and lifetime (P = 0.70) or baseline AD (P = 0.56). Nineteen percent (n = 42) of patients consulted psychosocial oncology services and 15% (n = 34) took psychiatric medication; 18.2% and 11.8% in the high MME group vs 5.5% and 7.3% in the low MME group (P = 0.006).
There was a total of 931 prescriptions over 143 physicians, representing 18 specialties with most prescribing being: ENT specialists (31.5%), gastroenterologists (17.0%), ER physicians (11.4%), and medical oncologists (6.0%). A centroid-based k-means clustering analysis revealed two clusters of higher and lower prescribing physicians.
Higher prescribing physicians included five physicians of different specialties, covering 47 prescriptions (47/931; 5.0%) on a total of six patients (6/223; 2.7%). Clustering was not included in the regression since clusters appeared patient based rather than physician based.
Opioid prescriptions did not significantly differ according to pain type Table 2 for complete results of the multiple linear regression.
Categorizing MME scores into High vs Low MME did not render a different portrait (see Table 1 ). However, patients with High MME presented lower levels of quality of life at 3, 6, and 12 months and higher HN-related symptoms at 3 months, mostly related to eating impairments (Table S3) . paired with the stress reactivity of a pre-existent AD may reinforce pain neuro-circuitry and lower pain thresholds. 22 The interface between HNC stress and pain mechanisms would merit further study, considering the known dysregulation of physiological systems in acute and chronic stress, such as the noradrenergic, HPA-cortisol, glutamatergic-NMDA, GABAergic, endocannabinoid, and oxytocin systems. 23 The above equivalence of opioid prescriptions in advanced cancer, with or without AD, needs consideration in light of the found trend towards the main effect of AD in an opposite direction than originally expected, whereby patients with an AD tended to be under-prescribed opioids. It is unclear if this was a result of patients with AD presenting a lower threshold for opioid responsiveness, of the prescribed opioids acting as an anti-anxiety agent that, in turn, allowed for better pain tolerance and less need for opioids, of FIGURE 2 Cumulated 12-month MME average in patients with head and neck cancer prescribed opioids TABLE 1 Sociodemographic, medical, and clinical characteristics of the sample with characterization of MME low and high subgroups, as well as their association with cumulative standardized MME opioid prescription dose over 1-year post-HNC diagnosis Variable MME Total n (%)-Mean (s.d.) a n = 189 P a MME Low n (%) n = 173 MME High n (%) n = 15 P Abbreviation: n/a, not applicable.
patients with early-stage cancer and AD driving this association, or of doctors under-prescribing opioids in patients with AD, perceiving the presenting problem as a need to treat the AD and being sensitized to the risk for opioid dependency. This negative trend would appear to be problematic in light of the low uptake of anti-anxiety medication (7.3%-11.8%).
While a SCID-I SUD diagnosis was not statistically significant, one must still consider the possibility of chemical coping in a subgroup of HNC, ie, the use of opioids and its derivatives to cope with life stressors (eg, psychosocial pain, existential suffering) rather than for physical pain per se. 24 This phenomenon, prevalent in general oncology, can be detrimental to quality of life due to opioid toxicity risk. 25, 26 Chemical coping may apply to a subgroup of patients with HNC considering its considerable addictive behavior etiology (eg, tobacco, alcohol) and corresponding genetic vulnerability, 27 as well as in those experiencing demoralization post-treatment when struggles with loss of function and limitations in activities of daily living are common. 28, 29 It is plausible that a subgroup of patients turn to opioids since they can no longer drink alcohol to cope due to impairments in swallowing or pain. Of merit is the finding that patients prescribed more opioids also increasingly used psychosocial oncology services, and that physician prescribing patterns were patient specific. HNC physicians may be sensitized to the concept of "total pain" considering the population, and more inclined to refer patients experiencing pain to psychosocial oncology. These patients may be motivated to consult to find alternative methods of alleviating pain and to readjust to the impact of pain on activities of daily living and participation in life roles. 30 Future research is needed to better appreciate shared decision-making, communication, and interpersonal dynamics around pain prescriptions in HNC clinics, as well as around adjunct anti-anxiety medication considering its sub-optimal uptake in patients. This is especially important in light of compromised quality of life and HNC-related physical symptoms.
| Clinical implications
Our findings emphasize the importance of treating pain through an interdisciplinary and multi-modal framework, including prophylactic pharmacological, psychosocial, and integrative therapies, with an emphasis on adequately addressing the sources of suffering. 31 One may want to use a stepped-care approach for anxiety management in HNC clinics, whereby all patients are presented with anxiety selfmanagement information and tools (ie, computer-based programs and/or pamphlets) and are systematically screened for anxiety (including lifetime and upon HNC AD) along the full care trajectory. 32, 33 This screening can be reviewed by the attending physician and/or nurse, who can refer patients early-on for further treatment in psychooncology (ie, psychologist, psychiatrist, social worker). 34, 35 In addition to pharmacotherapy, several therapies have been found to be effective in pain management, including coping skills training, hypnosis, and cognitive-behavioral therapy (eg, reframing catastrophizing thoughts, relaxation with guided imagery). 36 
| Study limitations
With regards to our new study findings and contribution to current bodies of literature, several limitations are noteworthy. First, we lack knowledge of actual opioid use, as our data is based on prescriptions. 
